{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Commiphora mukul", "Phyllanthus emblica", "Type 2 diabetes mellitus", "Vildagliptin", "dipeptidyl peptidase-IV inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34854407", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "10"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "10"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.4103/ijp.IJP_69_19"], "Journal": {"ISSN": "1998-3751", "JournalIssue": {"Volume": "53", "Issue": "5", "PubDate": {"Year": "2021", "Season": "Sep-Oct"}}, "Title": "Indian journal of pharmacology", "ISOAbbreviation": "Indian J Pharmacol"}, "ArticleTitle": "Antidiabetic activity of <i>Commiphora mukul</i> and <i>Phyllanthus emblica</i> and Computational analysis for the identification of active principles with dipeptidyl peptidase IV inhibitory activity.", "Pagination": {"StartPage": "384", "EndPage": "387", "MedlinePgn": "384-387"}, "Abstract": {"AbstractText": ["The medicinal plants may serve as natural alternatives to synthetic antidiabetic medications such as dipeptidyl peptidase-IV (DPP-IV) inhibitors, which are commonly prescribed in clinical practise. The medicinal plants: Commiphora mukul and Phyllanthus emblica have considerable DPP-IV inhibitory efficacy, according to our findings. The present study is an extension of the previous study conducted in our laboratory and was designed to confirm the antidiabetic effects of C. mukul and P. emblica in the streptozotocin diabetes model and elucidate the active principles responsible for DPP-IV inhibition. C. mukul (Guggul) and P. emblica (Amla) have the ability to inhibit DPP-IV and have anti-diabetic properties in a Type 2 diabetes mellitus experimental model. The binding sites and affinity of the active principles of C. mukul (Gluggusterone E, Gluggusterone Z) and P. emblica (Pzrogallol, beta-glucogallin, and gallic acid) responsible for DPP-IV enzyme inhibition were identified using in silico studies and compared to Vildagliptin, a synthetic DPP-IV inhibitor. The Vildagliptin and therapy groups had significantly lower glycated hemoglobin and DPP-IV levels. The anti-diabetic effect of C. mukul and P. emblica is due to their DPP-IV inhibitory action. The DPP-IV inhibitory action of Gluggusterone E, Gluggusterone Z, and beta-Glucogallin was found to be superior to Vildagliptin in docking tests."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India."}], "LastName": "Mohanty", "ForeName": "Ipseeta Ray", "Initials": "IR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biotechnology and Bioinformatics, DY. Patil Deemed to be University, Navi Mumbai, Maharashtra, India."}], "LastName": "Kumar", "ForeName": "C Selvaa", "Initials": "CS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India."}], "LastName": "Borde", "ForeName": "Manjusha", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "India", "MedlineTA": "Indian J Pharmacol", "NlmUniqueID": "7902477", "ISSNLinking": "0253-7613"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Dipeptidyl-Peptidase IV Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "EC 3.4.14.5", "NameOfSubstance": "Dipeptidyl Peptidase 4"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Commiphora"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": ["drug effects"], "DescriptorName": "Dipeptidyl Peptidase 4"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Dipeptidyl-Peptidase IV Inhibitors"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": [], "DescriptorName": "Phyllanthus emblica"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plant Leaves"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}], "CoiStatement": "None"}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829\u201335.", "ArticleIdList": ["8100523"]}, {"Citation": "Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:48\u201356.", "ArticleIdList": ["23837679"]}, {"Citation": "Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources. Evid Based Complement Alternat Med. 2014;2014:525340.", "ArticleIdList": ["PMC4020364", "24872833"]}, {"Citation": "Bharti SK, Sharma NK, Kumar A. Dipeptidyl peptidase IV inhibitory activity of seed extracts of Castanospermum austral and molecular docking of their alkaloids. J Herb Med. 2012;1:1\u20137."}, {"Citation": "Borde M, Mohanty IR, Suman RK. Dipeptidyl peptidase-IV inhibitory activities of medicinal plants: Terminalia arjuna, Commiphora mukul, Gymnema sylvestre, Morinda citrifolia, Emblica officinalis. Asian J Pharm Clin Res. 2016;3:180\u20132."}, {"Citation": "Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem. 2009;24:1061\u20136.", "ArticleIdList": ["19640223"]}, {"Citation": "Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917) Cancer Chemother Rep. 1963;29:91\u20138.", "ArticleIdList": ["13990586"]}, {"Citation": "Kaelin DE, Smenton AL, Eiermann GJ, He H, Leiting B, Lyons KA, et al. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 2007;17:5806\u201311.", "ArticleIdList": ["17851076"]}, {"Citation": "Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202\u201313.", "ArticleIdList": ["PMC4702940", "26400175"]}, {"Citation": "Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34:W116\u20138.", "ArticleIdList": ["PMC1538779", "16844972"]}, {"Citation": "Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7:197\u2013201.", "ArticleIdList": ["5959122"]}, {"Citation": "Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9\u201324.", "ArticleIdList": ["10588446"]}, {"Citation": "Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187\u2013218.", "ArticleIdList": ["17353295"]}, {"Citation": "Kshirsagar AD, Aggarwal AS, Harle UN, Deshpande AD. DPP IV inhibitors: Successes, failures and future prospects. Diabetes Metab Syndr. 2011;5:105\u201312.", "ArticleIdList": ["22813415"]}, {"Citation": "Borde MK, Mohanty IR, Maheshwari U. DPP-4 inhibitory activity and myocardial salvaging effects of Commiphora mukul in experimental diabetes. Int J Basic Clin Pharmacol. 2019;8:575\u201383."}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "12", "Day": "2", "Hour": "8", "Minute": "46"}, {"Year": "2021", "Month": "12", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34854407", "PMC8641738", "10.4103/ijp.IJP_69_19", "Indian J Pharmacol_2021_53_5_384_331085"]}}], "PubmedBookArticle": []}